

# Most Cost-Effective Setting Program Drug List

Established in 2012, the Most Cost-Effective Setting (MCES) Program requires that Independence Blue Cross (Independence) approve the treatment setting for certain medications eligible for coverage under the Independence medical benefit.

The main goal of the MCES Program is to manage the total cost of care by ensuring that members meet the coverage criteria in our medical policy, and that the requested treatment setting for these members is both safe and cost-effective. This review is conducted as part of the precertification process for members enrolled in Commercial medical plans.

Drug	Date Added to Program
Actemra®	September 1, 2017
Adakveo®	February 1, 2020
Amvuttra	July 1, 2022
Aralast NP®	July 1, 2012
Asceniv™	January 1, 2012*
Avsola™	February 1, 2020
Benlysta®	June 1, 2018
Bivigam®	January 1, 2012*
Cerezyme®	January 1, 2012
Cinqair®	July 1, 2020
Crysvita®	October 1, 2018
Cutaquig®	January 1, 2012*
Cuvitru™	January 1, 2012*
Elelyso™	July 1, 2012
Enjaymo™	July 1, 2022
Entyvio®	September 1, 2017
Evenity®	July 1, 2019
Evkeeza®	April 1, 2021
Fabrazyme®	July 1, 2012
Flebogamma®	January 1, 2012*
Flebogamma® DIF	January 1, 2012*
Fulphila™	June 25, 2018
Fylnetra™	July 1, 2022
Gamastar® S/D	January 1, 2012*
Gamifant®	November 20, 2018
Gammagard® Liquid	January 1, 2012*
Gammagard® S/D	January 1, 2012*
Gammaked™	January 1, 2012*
Gammaplex®	January 1, 2012*
Gamunex® C	January 1, 2012*
Givlaari™	February 1, 2020
Glassia®	July 1, 2012
Hizentra®	January 1, 2012*
HyQvia®	January 1, 2012*

Drug	Date Added to Program
Ilaris®	January 1, 2019
Ilumya™	November 1, 2018
Inflectra®	September 1, 2017
infliximab (unbranded)	February 15, 2022
Ixifi™	June 1, 2018
Kanuma®	November 1, 2018
Leqvio®	February 15, 2022
Lumizyme®	July 1, 2012
Naglazyme®	October 1, 2018
Neulasta®	January 1, 2017
Neulasta® Onpro®	January 1, 2017
Neupogen®	January 1, 2022
Nexvazyme™	September 15, 2021
Nyvepria™	October 1, 2020
Ocrevus™	January 1, 2018
Octagam®	January 1, 2012*
Onpattro™	August 10, 2018
Orencia®	September 1, 2017
Oxlumo™	January 1, 2021
Panzyga®	January 1, 2012*
Phesgo™	October 1, 2020
Privigen®	January 1, 2012*
Prolastin®	July 1, 2012
Prolia®	July 1, 2013
Radicava™	January 1, 2018
Reblozyl®	February 1, 2020
Releuko™	July 1, 2022
Remicade®	September 1, 2017
Renflexis®	September 1, 2017
Revcovi™	November 1, 2018
Sandostatin® LAR depot	January 1, 2017
Saphnelo™	September 15, 2021
Simponi Aria®	September 1, 2017
Soliris®	January 1, 2012

Drug	Date Added to Program
Somatuline <sup>®</sup> depot	January 1, 2018
Stelara <sup>®</sup>	July 1, 2013
Tepezza <sup>®</sup>	April 1, 2021
Tezspire <sup>™</sup>	July 1, 2022
Tysabri <sup>®</sup>	September 1, 2019
Udenyca <sup>™</sup>	November 2, 2018
Ultomiris <sup>™</sup>	December 21, 2018
Uplizna <sup>™</sup>	October 1, 2020
Vimizim <sup>®</sup>	August 1, 2014
VPRIV <sup>®</sup>	January 1, 2012
Vyepti <sup>™</sup>	July 1, 2020
Vyvgart <sup>™</sup>	February 15, 2022
Xembify <sup>®</sup>	January 1, 2012*
Xolair <sup>®</sup>	July 1, 2013
Zemaira <sup>®</sup>	July 1, 2012
Ziextenzo <sup>®</sup>	February 1, 2020

This list is subject to change. All biosimilars to a reference product in this program are subject to precertification review for most cost-effective setting.

\* The intravenous/subcutaneous immunoglobulin (IVIG/SCIG) class of drugs was added to the Most Cost-Effective Setting Program on January 1, 2012.

Some drugs in this class were approved by the U.S. Food and Drug Administration after this date, but they reflect the January 1, 2012 date to indicate when program requirements went into effect for all drugs in that class.